




The CRASH-3 trial has now randomised an incredible **4,000** patients internationally!

This means that there are still **6,000** patients to randomise before the trial is planned to end in **December 2016**.


# NEWSLETTER Special Edition



## Welcome to the team, Japan!

Earlier this month, the first ever CRASH-3 Japan national meeting was held at Senshu Trauma and Critical Care Centre in Osaka. The meeting was an excellent opportunity for collaborators from 10 hospitals across Japan to meet and establish a clear strategy to take the trial forward. Thank you to everyone who attended – we look forward to a very successful collaboration! *Jemma and the CRASH-3 team.*

Overall CRASH-3 trial recruitment



Every patient counts



### Japan National Meeting – April 2015




“The first meeting of CRASH-3 collaborators in Japan was a huge success. It was a great opportunity to reassure how samurai doctors are eager, earnest and inspired with this fantastic trial. The diligence of the Japanese nation is already well known to the world, and we’ll soon prove it again!”  
*Dr Yasushi Hagihara, National Coordinator*





The meeting established a clear plan for increasing the number of participating centres in Japan. The focus will be on mid-sized hospitals and all collaborators will invite their colleagues in other institutions to join. There's also the opportunity to convene local meetings and a plan to establish a strong group of hospitals in and around Osaka.




Many thanks to Dr Yasushi Hagihara and his team for hosting the national meeting at their hospital.



The teams at **Matsudo City Hospital** and **Senshu Trauma and Critical Care Centre** are doing amazingly well at randomising patients, well done everyone!

**Matsudo City Hospital**  
– **33 patients!**



**Senshu Trauma and Critical Care Centre**  
– **20 patients!**



The team at Matsudo City Hospital. Left to right: Hideki Endo, PI Tomohisa Shoko, Kan Saito, Ayako Kouta, Sho Furukawa

“We wanted to participate in the CRASH-3 trial because we were excited about the results of the CRASH-2 trial. It had a big impact on the practice of trauma patients in Japan. TXA is so common in Japan that every physician knows the drug, and it is used in various bleeding conditions. It is amazing that this kind of commonly used drug has such an effect. It may sound odd but some doctors still don't believe that this inexpensive drug, which has been routinely used without evidence for decades in Japan, has a big impact. More surprisingly, TXA was invented in Japan! So, why not participate from Japan? This is our first participation in an international randomized trial. We are very glad that we are able to be part of it. We would like to thank Ian Roberts and his team for his visit and their assistance.”  
*Dr Tomohisa Shoko, Matsudo City Hospital*